Physician profile
Laura M Lanier
NPI 1609239672
$3,814.47
in general payments reported to CMS, 2019-2025
20 companies · $612 in 2025
The $612 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $471 · 2023: $889 · 2024: $1,592 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.36 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,021.14 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $696.14 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $515.39 | 2022-2025 | Contrave, Onzetra Xsail, Nexletol |
| Astrazeneca Pharmaceuticals Lp | $511.02 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $370.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $121.97 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $106.62 | 2023-2024 | Quviviq |
| Pfizer INC. | $78.43 | 2023-2025 | |
| Exact Sciences Corporation | $69.81 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.71 | 2022-2024 | Jardiance, Synjardy |
| Phathom Pharmaceuticals, INC. | $42.62 | 2025 | Voquezna |
| Lundbeck LLC | $40.93 | 2024 | Rexulti |
| Abbott Laboratories | $39.86 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $29.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.01 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.36 | 2023 | |
| Astellas Pharma US INC | $19.95 | 2024 | Veozah |
| Vanda Pharmaceuticals INC. | $16.29 | 2024 | Fanapt, Hetlioz |
| Amgen INC. | $15.78 | 2024 | Otezla, Repatha |
| Hikma Pharmaceuticals USA | $14.69 | 2024 | Kloxxado, Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.